NASDAQ · VIR

Vir Biotechnology, Inc.

$8.69 -$0.65 (-6.96%) 1D After hours

Key Metrics

$1.58B
Market cap
P/E · TTM
$65.50M
Revenue · TTM
−$442.72M
Net income
EPS · TTM $-3.22
Dividend yield
Free cash flow −$449.64M
Beta · 1Y 1.79
EBITDA · TTM −$430.72M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 10
    From its Apr 20 high, the share price fell 26%.

    Peak close $11.09 on Apr 20; trough close $8.25 on Jun 10. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -26%
  • May 7
    The stock moved -9.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 7
  • Feb 24
    The stock moved +27.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 24

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.58B
Enterprise value
Shares outstanding168.7M
52-wk range$4.16 – $11.66
Avg volume · 20D1.4M
Net cash
Book value / share$5.91
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Vir Biotechnology, Inc.
IPO dateOct 11, 2019
Employees367

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S24.05
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -675.4%
Net -676.0%
FCF -686.5%
ROE / ROIC -45.1% · -129.3%

Financial Health

Current ratio7.11
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$449.43M

Cash Flow · TTM

Operating CF −$446.05M
Capex −$3.59M
Free cash flow −$449.64M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

1.8
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings